Venetoclax (ABT-199; GDC-0199)

Alias: Venclexta; GDC0199; ABT 199; RG7601;GDC0199; ABT-199; RG7601; GDC 0199; ABT199; RG 7601; Venetoclax
Cat No.:V0001 Purity: ≥98%
Venetoclax (formerly known as ABT-199 or GDC-0199; Venclexta) is a potent, selective andorally bioavailablesmall molecule inhibitor of theanti-apoptotic protein BCL-2 (B-cell lymphoma-2) with Ki of<0.01 nM.
Venetoclax (ABT-199; GDC-0199) Chemical Structure CAS No.: 1257044-40-8
Product category: Bcl-2
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
Other Sizes

Other Forms of Venetoclax (ABT-199; GDC-0199):

  • Venetoclax-d8
Top Publications Citing lnvivochem Products
InvivoChem's Venetoclax (ABT-199; GDC-0199) has been cited by 1 publication
Purity & Quality Control Documentation

Purity: ≥98%

Purity: ≥98.1%

Purity: ≥98%

Product Description

Venetoclax (formerly known as ABT-199 or GDC-0199; Venclexta) is a potent, selective and orally bioavailable small molecule inhibitor of the anti-apoptotic protein BCL-2 (B-cell lymphoma-2) with Ki of<0.01 nM. On April 11, 2016, the FDA authorized venetoclax for use in CLL patients who have a 17p deletion (a deletion on the short arm of chromosome 17) and who have received at least one prior therapy. Venetoclax works as a BCL-2 inhibitor by mimicking BH3, which is the native ligand of BCL-2. It prevents the anti-apoptotic BCL-2 protein, causing CLL cells to undergo programmed cell death.

Biological Activity I Assay Protocols (From Reference)
Bcl-2 (Ki = 0.01 nM); Bcl-xL (Ki = 48 nM); Bcl-W (Ki = 245 nM)
ln Vitro
ABT-199 shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. ABT-199 exhibits weak activity against FL5.12-Bcl-xL cells with an EC50 of 261 nM, but potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50s of 4 nM and 8 nM. In RS4;11 cells, ABT-199 causes a rapid apoptosis that is accompanied by the release of cytochrome c, activation of caspase, externalization of phosphatidylserine, and accumulation of sub-G0/G1 DNA. According to quantitative immunoblotting, Bcl-2 expression was strongly correlated with ABT-199 sensitivity in cell lines from NHL, DLBCL, MCL, AML, and ALL. The average EC50 for ABT-199 inducing apoptosis in CLL is 3.0 nM. [1]
ln vivo
ABT-199 (100 mg/kg) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. ABT-199 can be used alone or in combination with other drugs, such as SDX-105, to inhibit the growth of xenografts (DoHH2, Granta-519). [1]
Enzyme Assay
Binding affinities (Ki or IC50) of ABT-199 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The peptide probe and protein pairs used are as follows: : f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). A time-resolved fluorescence resonance energy transfer assay is also used to determine the binding affinities for Bcl-xL. At room temperature, for 30 minutes, Bcl-xL (1 nM, His tagged), 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-199 are combined.
Cell Assay
RS4;11 cells are treated with ABT-199 diluted in half-log steps starting at 1 μM-0.05 nM after being seeded at a density of 5 × 104 per well in 96-well plates. ABT-199 is incubated with leukemia and lymphoma cell lines for 48 hours after they have been seeded at 1.5-2 × 104 cells per well in the appropriate medium. Using the Cell TiterGlo reagent, effects on proliferation are assessed. The concentration-response data are analyzed using nonlinear regression to determine the EC50 values.
Animal Protocol
Mice: Nonobese diabetic/severe combined immunodeficient γ (NSG) mice are given a 150 µL injection of phosphate-buffered saline containing 5×106 luciferase-labeled LOUCY cells at the age of 6 weeks in the tail vein. The IVIS Lumina II imaging system measures the bioluminescence at regular intervals. After the cells have engrafted and the mice have been randomly split into two groups at 6 weeks (each group contains an equal number of males and females), the treatment is initiated on day 0 of the experiment. Venetoclax (ABT-199) 100 mg/kg body weight or vehicle is administered orally to mice for 4 days in a row. Days 0, 2, and 4 are used to measure the bioluminescene.

[1]. Nat Med. 2013 Feb;19(2):202-8.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
Molecular Weight
Exact Mass
Elemental Analysis
C, 62.24; H, 5.80; Cl, 4.08; N, 11.29; O, 12.90; S, 3.69
Related CAS #
Yellow solid powder
InChi Key
InChi Code
Chemical Name
Venclexta; GDC0199; ABT 199; RG7601;GDC0199; ABT-199; RG7601; GDC 0199; ABT199; RG 7601; Venetoclax
HS Tariff Code

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~100 mg/mL (~115.1 mM)
Water: <1 mg/mL(slightly soluble or insoluble)
Ethanol: <1 mg/mL
Solubility (In Vivo)
5% DMSO+50% PEG 300+5% Tween 80+ddH2O: 5 mg/mL (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.1515 mL 5.7575 mL 11.5149 mL
5 mM 0.2303 mL 1.1515 mL 2.3030 mL
10 mM 0.1151 mL 0.5757 mL 1.1515 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.


Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05464836 Not yetrecrulting Drug: CB-103/Drug:Venetoclax LeukemiaLymphoblastic]Leukemta M.D.Anderson Cancer Center December 30 2022 Phase 2
NCT05360160 Recruiting DrugSNDX-5613DrugVenetoclax]Drug-ASTX727 LeukemiaLymphoblastic]Leukemta M.D.Anderson Cancer Centerastex PharmaceuticalsIncSyndax Pharmaceutic als inc December 30 2022 Phase 2


Biological Data
Related Products
Contact Us